Kenneth S. Cohen to Angiogenesis Inhibitors
This is a "connection" page, showing publications Kenneth S. Cohen has written about Angiogenesis Inhibitors.
Connection Strength
0.223
-
Therapeutic activity of high-dose intratumoral IFN-ß requires direct effect on the tumor vasculature. J Immunol. 2014 Oct 15; 193(8):4254-60.
Score: 0.100
-
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nat Clin Pract Oncol. 2007 May; 4(5):316-21.
Score: 0.060
-
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004 Feb; 10(2):145-7.
Score: 0.048
-
Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol. 2006 Mar 20; 24(9):1449-53.
Score: 0.014